Study of decade-long leukemia remissions after Car T reveals new details about persistence of personalized cells
Lowering homocysteine with vitamin supplements to treat drug-resistant hypertension
2 February 2022Amid a national mental health crisis for kids, here’s how parents can help
2 February 2022Study of decade-long leukemia remissions after Car T reveals new details about persistence of personalized cells
In the summer of 2010, Bill Ludwig and Doug Olson were battling an insidious blood cancer called chronic lymphocytic leukemia (CLL). They’d both received numerous treatments, and as remaining options became scarce, they volunteered to become the first participants in a clinical trial of an experimental therapy underway at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. The treatment would eradicate their end-stage leukemia, generate headlines across the globe, and usher in a new era of highly personalized medicine.
